References

Gd-DTPA relaxivity depends on macromolecular content

10.1002/1522-2594(200011)44:5<665::aid-mrm1>3.0.co;2-m · ExternalCitation · doi-reference

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

10.1002/ajh.21656 · ExternalCitation · doi-reference

Collagen-targeted MRI contrast agent for molecular imaging of fibrosis

10.1002/anie.200700700 · ExternalCitation · doi-reference

Multifunctional core–shell silica nanoparticles for highly sensitive (19)F magnetic resonance imaging

10.1002/anie.201308500 · ExternalCitation · doi-reference

Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure

10.1002/art.22925 · ExternalCitation · doi-reference

Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders

10.1002/art.22926 · ExternalCitation · doi-reference

Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents

10.1002/cmmi.100 · ExternalCitation · doi-reference

Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications

10.1002/cmmi.146 · ExternalCitation · doi-reference

1991 I.I. Rabi Award. Estimating oxygen saturation of blood in vivo with MR imaging at 1.5 T

10.1002/jmri.1880010303 · ExternalCitation · doi-reference

Water diffusion and exchange as they influence contrast enhancement

10.1002/jmri.1880070114 · ExternalCitation · doi-reference

Relaxation enhancing properties of MnDPDP in human myocardium

10.1002/jmri.20200 · ExternalCitation · doi-reference

An apparent unidirectional influx constant for manganese as a measure of myocardial calcium channel activity

10.1002/jmri.20736 · ExternalCitation · doi-reference

Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction

10.1002/jmri.21065 · ExternalCitation · doi-reference

Efficacy of whole-blood model of gadolinium-based contrast agent relaxivity in predicting vascular MR signal intensity in vivo

10.1002/jmri.29089 · ExternalCitation · doi-reference

Molecular factors that determine Curie spin relaxation in dysprosium complexes

10.1002/mrm.1277 · ExternalCitation · doi-reference

Dependence of MR signal intensity on Gd tissue concentration over a broad dose range

10.1002/mrm.1910220205 · ExternalCitation · doi-reference

Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange

10.1002/mrm.1910360608 · ExternalCitation · doi-reference

A multinuclear MR study of Gd-EOB-DTPA: comprehensive preclinical characterization of an organ specific MRI contrast agent

10.1002/mrm.1910380415 · ExternalCitation · doi-reference

A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents

10.1002/mrm.20684 · ExternalCitation · doi-reference

Evidence for weak protein binding of commercial extracellular gadolinium contrast agents

10.1002/mrm.22214 · ExternalCitation · doi-reference

Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI

10.1002/mrm.25454 · ExternalCitation · doi-reference

Noninvasive quantification of fibrosis in skeletal and cardiac muscle in mdx mice using EP3533 enhanced magnetic resonance imaging

10.1002/mrm.27578 · ExternalCitation · doi-reference

Development of specialized magnetic resonance acquisition techniques for human hyperpolarized [(13) C,(15) N(2) ]urea + [1-(13) C]pyruvate simultaneous perfusion and metabolic imaging

10.1002/mrm.29266 · ExternalCitation · doi-reference

Current methods for hyperpolarized [1-(13)C]pyruvate MRI human studies

10.1002/mrm.29875 · ExternalCitation · doi-reference

Probing human heart TCA cycle metabolism and response to glucose load using hyperpolarized [2-(13) C]pyruvate MRS

10.1002/nbm.5074 · ExternalCitation · doi-reference

Extracellular MRI contrast agents based on gadolinium

10.1007/3-540-45733-x_1 · ExternalCitation · doi-reference

Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol

10.1007/s00330-001-1242-9 · ExternalCitation · doi-reference

Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide

10.1007/s00330-006-0495-8 · ExternalCitation · doi-reference

MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients

10.1007/s00330-008-0965-2 · ExternalCitation · doi-reference

Characterization of early neovascular response to acute lung ischemia using simultaneous (19)F/(1)H MR molecular imaging

10.1007/s10456-013-9377-2 · ExternalCitation · doi-reference

Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat

10.1016/0730-725x(92)90378-d · ExternalCitation · doi-reference

Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil

10.1016/0730-725x(95)00024-b · ExternalCitation · doi-reference

RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: influence of pre or post-functionalization on capsule morphology

10.1016/j.ejpb.2013.12.003 · ExternalCitation · doi-reference

Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis

10.1016/j.jaad.2006.10.047 · ExternalCitation · doi-reference

Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis

10.1016/j.jaad.2007.01.022 · ExternalCitation · doi-reference

Impaired myocardial calcium uptake in patients with diabetes mellitus: a manganese-enhanced cardiac magnetic resonance study

10.1016/j.jcmg.2023.05.009 · ExternalCitation · doi-reference

Gaussian approximation in the theory of MR signal formation in the presence of structure-specific magnetic field inhomogeneities. Effects of impermeable susceptibility inclusions

10.1016/j.jmr.2003.11.006 · ExternalCitation · doi-reference

Self-reported gadolinium toxicity: a survey of patients with chronic symptoms

10.1016/j.mri.2016.05.005 · ExternalCitation · doi-reference

Gadolinium tissue deposition in brain and bone

10.1016/j.mri.2016.08.025 · ExternalCitation · doi-reference

Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium

10.1016/j.yadr.2007.07.002 · ExternalCitation · doi-reference

Nuclear magnetic resonance transverse relaxation times of water protons in skeletal muscle

10.1016/s0006-3495(74)85937-0 · ExternalCitation · doi-reference

Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours

10.1016/s0140-6736(84)92852-6 · ExternalCitation · doi-reference

Chemistry of MRI contrast agents: current challenges and new frontiers

10.1021/acs.chemrev.8b00363 · ExternalCitation · doi-reference

Highly efficient activatable MRI probe to sense myeloperoxidase activity

10.1021/acs.jmedchem.1c00038 · ExternalCitation · doi-reference

Peroxidase sensitive amplifiable probe for molecular magnetic resonance imaging of pulmonary inflammation

10.1021/acssensors.9b01010 · ExternalCitation · doi-reference

Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications

10.1021/cr980440x · ExternalCitation · doi-reference

Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent

10.1021/ic049559g · ExternalCitation · doi-reference

The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates

10.1021/ja017168k · ExternalCitation · doi-reference

EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus

10.1021/ja800834y · ExternalCitation · doi-reference

Dual hydrazine-equipped turn-on manganese-based probes for magnetic resonance imaging of liver fibrogenesis

10.1021/jacs.2c06231 · ExternalCitation · doi-reference

Tailored chemical reactivity probes for systemic imaging of aldehydes in fibroproliferative diseases

10.1021/jacs.3c04964 · ExternalCitation · doi-reference

A manganese alternative to gadolinium for MRI contrast

10.1021/jacs.5b10748 · ExternalCitation · doi-reference

Pharmacokinetics and biodistribution of nanoparticles

10.1021/mp800049w · ExternalCitation · doi-reference

Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent

10.1038/nm.2310 · ExternalCitation · doi-reference

Multi-targeted (1)H/(19)F MRI unmasks specific danger patterns for emerging cardiovascular disorders

10.1038/s41467-021-26146-6 · ExternalCitation · doi-reference

Gadolinium and nephrogenic systemic fibrosis

10.1038/sj.ki.5002338 · ExternalCitation · doi-reference

Magnetic resonance imaging with superparamagnetic iron oxide fails to track the long-term fate of mesenchymal stem cells transplanted into heart

10.1038/srep09058 · ExternalCitation · doi-reference

A paramagnetic contrast agent with myeloperoxidase-sensing properties

10.1039/b601540a · ExternalCitation · doi-reference

The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists

10.1039/c8mt00302e · ExternalCitation · doi-reference

Case records of the Massachusetts general hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin

10.1056/nejmcpc0708697 · ExternalCitation · doi-reference

Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase

10.1073/pnas.0803945105 · ExternalCitation · doi-reference

Metabolism and pharmacokinetics of MnDPDP in man

10.1080/02841859709172400 · ExternalCitation · doi-reference

Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

10.1093/ndt/gfk062 · ExternalCitation · doi-reference

Contrast agents for magnetic resonance imaging: safety update

10.1097/00002142-200310000-00007 · ExternalCitation · doi-reference

Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals

10.1097/00004728-199911001-00022 · ExternalCitation · doi-reference

Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths

10.1097/01.rli.0000184756.66360.d3 · ExternalCitation · doi-reference

Imaging pathobiology of carotid atherosclerosis with ultrasmall superparamagnetic particles of iron oxide: an update

10.1097/hco.0000000000000413 · ExternalCitation · doi-reference

Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function

10.1097/rli.0000000000000252 · ExternalCitation · doi-reference

High levels of gadolinium deposition in the skin of a patient with normal renal function

10.1097/rli.0000000000000266 · ExternalCitation · doi-reference

Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases

10.1097/rli.0000000000000318 · ExternalCitation · doi-reference

Relaxivity of ferumoxytol at 1.5 T and 3.0 T

10.1097/rli.0000000000000434 · ExternalCitation · doi-reference

Tumor contrast enhancement and whole-body elimination of the manganese-based magnetic resonance imaging contrast agent Mn-PyC3A

10.1097/rli.0000000000000593 · ExternalCitation · doi-reference

Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity: erratum

10.1097/rli.0000000000000632 · ExternalCitation · doi-reference

Positron emission tomography-magnetic resonance imaging pharmacokinetics, in vivo biodistribution, and whole-body elimination of Mn-PyC3A

10.1097/rli.0000000000000736 · ExternalCitation · doi-reference

Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent

10.1097/rli.0000000000000889 · ExternalCitation · doi-reference

Divalent manganese complexes as potential replacements for gadolinium-based contrast agents

10.1097/rli.0000000000001053 · ExternalCitation · doi-reference

Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent

10.1097/rli.0b013e31804fa154 · ExternalCitation · doi-reference

Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T

10.1097/rli.0b013e318059b58b · ExternalCitation · doi-reference

High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent

10.1097/rli.0b013e31815a3407 · ExternalCitation · doi-reference

Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C

10.1097/rli.0b013e3181852171 · ExternalCitation · doi-reference

Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility

10.1097/rli.0b013e3181b092a7 · ExternalCitation · doi-reference

The nuclear induction experiment

10.1103/physrev.70.474 · ExternalCitation · doi-reference

Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis

10.1111/j.1365-2133.2007.08335.x · ExternalCitation · doi-reference

Multispectral fluorine-19 MRI enables longitudinal and noninvasive monitoring of tumor-associated macrophages

10.1126/scitranslmed.abo2952 · ExternalCitation · doi-reference

Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment

10.1126/scitranslmed.abq6297 · ExternalCitation · doi-reference

Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction

10.1136/heartjnl-2016-311018 · ExternalCitation · doi-reference

Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis

10.1136/heartjnl-2017-311688 · ExternalCitation · doi-reference

Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion

10.1136/jitc-2023-007015 · ExternalCitation · doi-reference

In situ decellularization of a large animal saccular aneurysm model: sustained inflammation and active aneurysm wall remodeling

10.1136/neurintsurg-2020-016589 · ExternalCitation · doi-reference

Assessment of stunned and viable myocardium using manganese-enhanced MRI

10.1136/openhrt-2021-001646 · ExternalCitation · doi-reference

Gadolinium-induced fibrosis

10.1146/annurev-med-063014-124936 · ExternalCitation · doi-reference

Vasculitis: molecular imaging by targeting the inflammatory enzyme myeloperoxidase

10.1148/radiol.11110040 · ExternalCitation · doi-reference

Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the food and drug administration

10.1148/radiol.12112783 · ExternalCitation · doi-reference

Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles

10.1148/radiol.13120789 · ExternalCitation · doi-reference

Vascular remodeling and plaque vulnerability in a rabbit model of atherosclerosis: comparison of delayed-enhancement MR imaging with an elastin-specific contrast agent and unenhanced black-blood MR imaging

10.1148/radiol.13130502 · ExternalCitation · doi-reference

High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material

10.1148/radiol.13131669 · ExternalCitation · doi-reference

High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration

10.1148/radiol.14140364 · ExternalCitation · doi-reference

Intracranial gadolinium deposition after contrast-enhanced MR imaging

10.1148/radiol.15150025 · ExternalCitation · doi-reference

Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis

10.1148/radiol.2017162740 · ExternalCitation · doi-reference

A manganese-based alternative to gadolinium: contrast-enhanced MR angiography, excretion, pharmacokinetics, and metabolism

10.1148/radiol.2017170977 · ExternalCitation · doi-reference

Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates

10.1148/radiol.2018181151 · ExternalCitation · doi-reference

Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: a pilot study

10.1148/radiol.2018181204 · ExternalCitation · doi-reference

Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI

10.1148/radiol.2019190477 · ExternalCitation · doi-reference

Four-dimensional multiphase steady-state MRI with ferumoxytol enhancement: early multicenter feasibility in pediatric congenital heart disease

10.1148/radiol.2021203696 · ExternalCitation · doi-reference

Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study

10.1148/radiol.2361040148 · ExternalCitation · doi-reference

Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy

10.1148/radiol.2362030847 · ExternalCitation · doi-reference

MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325

10.1148/radiol.2363040577 · ExternalCitation · doi-reference

Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent

10.1148/radiol.2473070975 · ExternalCitation · doi-reference

Carotid artery brain aneurysm model: in vivo molecular enzyme-specific MR imaging of active inflammation in a pilot study

10.1148/radiol.2523081426 · ExternalCitation · doi-reference

MS-325: albumin-targeted contrast agent for MR angiography

10.1148/radiology.207.2.9577506 · ExternalCitation · doi-reference

Molecular imaging

10.1148/radiology.219.2.r01ma19316 · ExternalCitation · doi-reference

In vivo MRI tracking of mesenchymal stromal cells labeled with ultrasmall paramagnetic iron oxide particles after intramyocardial transplantation in patients with chronic ischemic heart disease

10.1155/2019/2754927 · ExternalCitation · doi-reference

In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction

10.1161/01.cir.0000070931.62772.4e · ExternalCitation · doi-reference

Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells

10.1161/01.cir.0000084537.66419.7a · ExternalCitation · doi-reference

In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent

10.1161/01.cir.0000134960.31304.87 · ExternalCitation · doi-reference

Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent

10.1161/01.cir.0000158478.29668.9b · ExternalCitation · doi-reference

Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis

10.1161/atvbaha.113.302931 · ExternalCitation · doi-reference

In vivo assessment of aortic aneurysm wall integrity using elastin-specific molecular magnetic resonance imaging

10.1161/circimaging.113.001131 · ExternalCitation · doi-reference

Assessment of myocardial infarction and postinfarction scar remodeling with an elastin-specific magnetic resonance agent

10.1161/circimaging.113.001270 · ExternalCitation · doi-reference

Tropoelastin: a novel marker for plaque progression and instability

10.1161/circimaging.117.007303 · ExternalCitation · doi-reference

Cardiovascular molecular imaging with fluorine-19 MRI: the road to the clinic

10.1161/circimaging.123.014742 · ExternalCitation · doi-reference

Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized (13)C MRI

10.1161/circresaha.119.316260 · ExternalCitation · doi-reference

Effect of doxorubicin on myocardial bicarbonate production from pyruvate dehydrogenase in women with breast cancer

10.1161/circresaha.120.317970 · ExternalCitation · doi-reference

Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent

10.1161/circulationaha.104.522110 · ExternalCitation · doi-reference

Molecular magnetic resonance imaging of atrial clots in a swine model

10.1161/circulationaha.104.529941 · ExternalCitation · doi-reference

Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury

10.1161/circulationaha.107.756510 · ExternalCitation · doi-reference

Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model

10.1161/circulationaha.108.826388 · ExternalCitation · doi-reference

Noninvasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions

10.1161/circulationaha.114.010962 · ExternalCitation · doi-reference

Assessment of myocardial remodeling using an elastin/tropoelastin specific agent with high field magnetic resonance imaging (MRI)

10.1161/jaha.115.001851 · ExternalCitation · doi-reference

Contrast-enhanced cardiac magnetic resonance imaging with a manganese-based alternative to gadolinium for tissue characterization of acute myocardial infarction

10.1161/jaha.122.026923 · ExternalCitation · doi-reference

Simultaneous positron emission tomography and molecular magnetic resonance imaging of cardiopulmonary fibrosis in a mouse model of left ventricular dysfunction

10.1161/jaha.124.034363 · ExternalCitation · doi-reference

Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent

10.1161/strokeaha.106.479998 · ExternalCitation · doi-reference

Molecular MRI of intracranial thrombus in a rat ischemic stroke model

10.1161/strokeaha.109.575662 · ExternalCitation · doi-reference

Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent

10.1164/rccm.200503-379oc · ExternalCitation · doi-reference

Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis

10.1172/jci.insight.91506 · ExternalCitation · doi-reference

European cardiovascular magnetic resonance (EuroCMR) registry-multi national results from 57 centers in 15 countries

10.1186/1532-429x-15-9 · ExternalCitation · doi-reference

Regional quantification of cardiac metabolism with hyperpolarized [1-(13)C]-pyruvate CMR evaluated in an oral glucose challenge

10.1186/s12968-023-00972-7 · ExternalCitation · doi-reference

Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer

10.1186/s40425-018-0416-9 · ExternalCitation · doi-reference

Monitoring cell therapy using iron oxide MR contrast agents

10.2174/1389201043376526 · ExternalCitation · doi-reference

Incidence of immediate gadolinium contrast media reactions

10.2214/ajr.10.4885 · ExternalCitation · doi-reference

(19)F MRI in orthotopic cancer model via intratracheal administration of α(ν)β(3)-targeted perfluorocarbon nanoparticles

10.2217/nnm-2018-0051 · ExternalCitation · doi-reference

MRI application and challenges of hyperpolarized carbon-13 pyruvate in translational and clinical cardiovascular studies: a literature review

10.3390/diagnostics14101035 · ExternalCitation · doi-reference